Literature DB >> 30903025

Tapering bDMARDs in axial SpA - what is the current evidence?

Nelly R Ziade1,2, Xenofon Baraliakos3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30903025     DOI: 10.1038/s41584-019-0201-2

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China.

Authors:  Kun-Peng Li; Jing-Yu Jin; Jin-Shui Yang; Yan Li; Wei Zhao; Gui Luo; Jian Zhu; Jiang-Lin Zhang; Feng Huang
Journal:  Arch Med Sci       Date:  2018-06-01       Impact factor: 3.318

  1 in total
  1 in total

1.  Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view.

Authors:  Vasco C Romão; Inês Cordeiro; Carla Macieira; Filipa Oliveira-Ramos; José Carlos Romeu; Carlos Miranda Rosa; Maria João Saavedra; Fernando Saraiva; Elsa Vieira-Sousa; João Eurico Fonseca
Journal:  RMD Open       Date:  2020-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.